Capha Pharmaceuticals Inc.

Capha Pharmaceuticals Inc.

FPSUF
Capha Pharmaceuticals Inc.US flagOther OTC
0.00
USD
- -
- -
6,443.00Market Cap
Capha Pharmaceuticals Inc.
FPSUF
(Other OTC)

Recent

price

0.00

P/E

ratio

- -

div

yld

- -

ROIC.AI

2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
TTM
FRC
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Revenue per Share
-0.08
-0.27
-0.59
-0.03
-0.04
-0.02
- -
-0.02
- -
- -
- -
- -
- -
- -
- -
- -
- -
Basic EPS, GAAP
-0.06
-0.06
-0.18
-0.03
-0.02
-0.02
-0.03
-0.01
- -
- -
- -
- -
- -
- -
- -
- -
- -
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Dividend per Share
-0.92
-1.16
-1.42
-1.25
-1.07
-0.54
-0.25
-0.27
-0.08
-0.06
-0.06
-0.06
-0.06
-0.06
-0.07
-0.07
-0.07
Book Value per Share
0.42
0.36
0.01
0.02
0.01
0.01
0.01
- -
-0.01
- -
- -
- -
-0.01
-0.01
-0.01
-0.01
-0.01
Tangible Book Value per Share
6
6
9
10
13
30
55
54
54
64
64
64
64
64
64
64
64
Basic Weighted Avg Shares
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Sales/Revenue/Turnover
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Operating Margin (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Depreciation Expense
- -
-2
-5
- -
- -
-1
- -
-1
- -
- -
- -
- -
- -
- -
- -
- -
- -
Net Income, GAAP
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Effective Tax Rate (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Profit Margin (%)
1
2
- -
- -
- -
- -
1
- -
-1
- -
- -
- -
- -
- -
-1
-1
-1
Working Capital
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
LT Debt
3
2
- -
- -
- -
- -
1
- -
-1
- -
- -
- -
- -
- -
- -
-1
-1
Total Equity
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Common Equity (%)

Capital Structure

FRC

in mil. unless spec.
Dec'24
Mar'25
Jun'25
ST Debt
1
1
1
LT Borrowings
- -
- -
- -
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
64
64
64
Market Capitalization
- -
- -
- -

Working Capital

FRC

in mil. unless spec.
Dec'24
Mar'25
Jun'25
Total Current Assets
- -
- -
- -
Cash, Cash Equivalents & STI
- -
- -
- -
Accounts Receivable, Net
- -
- -
- -
Inventories
- -
- -
- -
Total Current Liabilities
1
1
1
Payables & Accruals
- -
- -
- -
ST Debt
1
1
1
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
33.73%
20.36%
14.16%
Free Cash Flow
-3.68%
10.91%
-3.19%
Net Income, GAAP
-97.26%
-2.13%
-1.73%
Sales/Revenue/Turnover
- -
- -
- -
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
- -
- -
- -
- -
- -
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -

Quarterly Earnings Per Share

FRC

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
- -
- -
- -
- -
- -
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -

Quarterly Dividends Per Share

FRC

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
- -
- -
- -
- -
- -
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
Business
Capha Pharmaceuticals Inc. (FPSUF) is a Canada-based pharmaceutical company focused on pharmaceutical distribution and exploring opportunities in the medical technology space; it intends to engage in the distribution of pharmaceutical products while producing and distributing items within the industry. Incorporated on August 28, 1998, and headquartered at 2417 Main Street Suite 52, West Kelowna, British Columbia V4T 2H8, the company operates primarily in Canada, serving domestic customers with its offerings in the biotech and pharma sub-industry. Formerly known as FPS Pharma Inc., it changed its name to Capha Pharmaceuticals Inc. in January 2017, marking a key rebranding to align with its strategic pivot toward pharmaceutical distribution and medtech exploration; no recent partnerships, acquisitions, funding rounds, or new product launches have been reported in the last 1-2 years.